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 Introduction 
Due to its unique properties of being an MR contrast agent and being transported by neurons in an activity-dependent 
manner, Mn has been widely used in different neurological applications [1]. However, its usage as neural tract tracer 
in longitudinal studies is limited by its toxicity [2]. Having found non-toxic doses of cold Mn being incapable of 
producing significant changes in the MRI signal, we investigated using no-carrier-added 52gMn [3] as a PET neural tract 
tracer. 
Methods 
In the first experiment, 16 rats were stereotactically injected to the ventral tegmental area (VTA) with 0, 5, 50 or 
200nmol of Mn2+ in 0,5µl. T2W images and T1 maps (FLASH sequence) were acquired before and 24h after the 
injection on a 7T MR scanner. Average T1 values from 5 brain regions were tested with two-way ANOVA, followed by 
the Tukey HSD test (Bonferroni corrected). 4 weeks later, the toxicity effects were evaluated with the rotameter test 
and the tyrosine hydroxylase (TH) staining. 
In the second study, 52gMn was produced on a small biomedical cyclotron, chemically isolated from proton irradiated Cr 
metal, and prepared for injection in saline. 8 rats were injected, with approx. 150 kBq, to the dorsolateral striatum 
(DLS) and 2 to the VTA via a guide cannula mounted on the skull 5-6 days earlier. They were scanned in a µPET 
scanner, and subsequently in the MR scanner, 7 or 12h later. Brains of 5 animals were used for autoradiography. PET 
images were reconstructed with the OSEM3D algorithm. 
Results 
The dose of 200nmol produced a significant drop in the T1 value in 3 brain regions. However, 200 and 50nmol doses 
caused a lesion of the neurons in the injection location. The lesion did not occur after injecting 0 or 5nmol of Mn [Fig. 
1]. The behavioral test did not reveal disturbances in the motor control system in any group. 
52gMn was obtained with > 99% radionuclidic purity and the specific activity of 7,5GBq/µmol. The non-radioactive Mn 
content was 7,0ng/MBq of 52gMn at 24h post-bombardment. Therefore, there was less than 0,07nmol of total Mn 
content injected in a 0,5µl volume which sufficed to produce strong signal in the PET images. 
52gMn transport to the ventral pallidum (VP) and nucleus accumbens (NAc) could be seen 12h after injection to the VTA 
[Fig. 2] and to the substantia nigra 7 or 12h after injection to the DLS. The autoradiograms confirmed the tracer 
location seen in the PET images. 
Conclusions 
Our data shows that the dose required for Mn-enhanced MRI measurements produces long-term toxicity. Therefore, 
we propose 52gMn as a new PET tracer for neural tracts imaging. Mn concentration needed for PET is expected to be 
non-toxic. Further studies will evaluate the tracer’s characteristics. 
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Mn toxicity: 
0, 5, 50 or 200nmol of Mn was 
injected to the right VTA. A. TH-
staining shows a lesion caused by 
the 50 and 200nmol doses. B. A 
drop in T1 value could be detected 
in 3 ipsilateral brain regions 24h 
after injecting the highest dose. 
N=4 * p<0,05 ** p<0,005 
Neural transport of Mn-52: 
A. 52gMn (152 kBq) was injected 
to the right VTA (white arrow) and 
its transport to the NAc (red arrows) 
could be seen 12h later. B. PET 
signal quantification shows the 
highest content of the tracer in the 
ipsilateral NAc and VP (bars 
represent mean+SEM). 
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